nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Daunorubicin—hematologic cancer	0.117	0.481	CrCtD
Epirubicin—Idarubicin—hematologic cancer	0.0889	0.365	CrCtD
Epirubicin—Anthracyclines—Daunorubicin—hematologic cancer	0.0698	0.22	CiPCiCtD
Epirubicin—TOP2A—hematologic cancer	0.0578	1	CbGaD
Epirubicin—Anthracyclines—Idarubicin—hematologic cancer	0.0529	0.167	CiPCiCtD
Epirubicin—YWHAG—Daunorubicin—hematologic cancer	0.0393	0.303	CbGbCtD
Epirubicin—Doxorubicin—hematologic cancer	0.0378	0.155	CrCtD
Epirubicin—Topoisomerase Inhibitors—Daunorubicin—hematologic cancer	0.0365	0.115	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Teniposide—hematologic cancer	0.031	0.0977	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Idarubicin—hematologic cancer	0.0277	0.0871	CiPCiCtD
Epirubicin—Doxorubicin—Daunorubicin—hematologic cancer	0.0252	0.16	CrCrCtD
Epirubicin—Valrubicin—Daunorubicin—hematologic cancer	0.0252	0.16	CrCrCtD
Epirubicin—Idarubicin—Daunorubicin—hematologic cancer	0.0252	0.16	CrCrCtD
Epirubicin—Topoisomerase Inhibitors—Mitoxantrone—hematologic cancer	0.0235	0.0741	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Irinotecan—hematologic cancer	0.0235	0.0741	CiPCiCtD
Epirubicin—Anthracyclines—Doxorubicin—hematologic cancer	0.0225	0.0708	CiPCiCtD
Epirubicin—Valrubicin—Idarubicin—hematologic cancer	0.0191	0.121	CrCrCtD
Epirubicin—Doxorubicin—Idarubicin—hematologic cancer	0.0191	0.121	CrCrCtD
Epirubicin—Daunorubicin—Idarubicin—hematologic cancer	0.0191	0.121	CrCrCtD
Epirubicin—Topoisomerase Inhibitors—Etoposide—hematologic cancer	0.0185	0.0581	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—hematologic cancer	0.0117	0.037	CiPCiCtD
Epirubicin—TOP2A—Idarubicin—hematologic cancer	0.0113	0.0871	CbGbCtD
Epirubicin—DHCR7—Doxorubicin—hematologic cancer	0.0103	0.0793	CbGbCtD
Epirubicin—YWHAG—Doxorubicin—hematologic cancer	0.0103	0.0793	CbGbCtD
Epirubicin—AURKA—Doxorubicin—hematologic cancer	0.0103	0.0793	CbGbCtD
Epirubicin—Idarubicin—Doxorubicin—hematologic cancer	0.0081	0.0516	CrCrCtD
Epirubicin—Daunorubicin—Doxorubicin—hematologic cancer	0.0081	0.0516	CrCrCtD
Epirubicin—Valrubicin—Doxorubicin—hematologic cancer	0.0081	0.0516	CrCrCtD
Epirubicin—TOP2A—Daunorubicin—hematologic cancer	0.00799	0.0616	CbGbCtD
Epirubicin—TOP2A—Teniposide—hematologic cancer	0.00694	0.0536	CbGbCtD
Epirubicin—ABCC1—Idarubicin—hematologic cancer	0.00626	0.0483	CbGbCtD
Epirubicin—TOP2A—Mitoxantrone—hematologic cancer	0.00485	0.0375	CbGbCtD
Epirubicin—ABCC1—Daunorubicin—hematologic cancer	0.00443	0.0342	CbGbCtD
Epirubicin—TOP2A—Etoposide—hematologic cancer	0.00306	0.0236	CbGbCtD
Epirubicin—ABCC1—Mitoxantrone—hematologic cancer	0.00269	0.0208	CbGbCtD
Epirubicin—ABCC1—Irinotecan—hematologic cancer	0.00212	0.0163	CbGbCtD
Epirubicin—TOP2A—Doxorubicin—hematologic cancer	0.00209	0.0161	CbGbCtD
Epirubicin—ABCC1—Vinblastine—hematologic cancer	0.00188	0.0145	CbGbCtD
Epirubicin—ABCC1—Vincristine—hematologic cancer	0.00185	0.0143	CbGbCtD
Epirubicin—ABCC1—Etoposide—hematologic cancer	0.0017	0.0131	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—hematologic cancer	0.00116	0.00893	CbGbCtD
Epirubicin—ABCC1—Methotrexate—hematologic cancer	0.00112	0.00865	CbGbCtD
Epirubicin—CHD1—hematopoietic system—hematologic cancer	0.000695	0.0552	CbGeAlD
Epirubicin—AURKA—hematopoietic system—hematologic cancer	0.000561	0.0445	CbGeAlD
Epirubicin—CHD1—gonad—hematologic cancer	0.000529	0.042	CbGeAlD
Epirubicin—DHCR7—hematopoietic system—hematologic cancer	0.000469	0.0372	CbGeAlD
Epirubicin—CHD1—blood—hematologic cancer	0.000461	0.0366	CbGeAlD
Epirubicin—CHD1—bone marrow—hematologic cancer	0.000446	0.0354	CbGeAlD
Epirubicin—YWHAG—hematopoietic system—hematologic cancer	0.00043	0.0341	CbGeAlD
Epirubicin—AURKA—gonad—hematologic cancer	0.000426	0.0338	CbGeAlD
Epirubicin—CHD1—lung—hematologic cancer	0.000404	0.0321	CbGeAlD
Epirubicin—CHD1—testis—hematologic cancer	0.000381	0.0302	CbGeAlD
Epirubicin—AURKA—blood—hematologic cancer	0.000371	0.0295	CbGeAlD
Epirubicin—AURKA—bone marrow—hematologic cancer	0.000359	0.0285	CbGeAlD
Epirubicin—DHCR7—gonad—hematologic cancer	0.000357	0.0283	CbGeAlD
Epirubicin—YWHAG—gonad—hematologic cancer	0.000327	0.026	CbGeAlD
Epirubicin—AURKA—lung—hematologic cancer	0.000326	0.0258	CbGeAlD
Epirubicin—PLA2G4A—hematopoietic system—hematologic cancer	0.000321	0.0255	CbGeAlD
Epirubicin—Daunorubicin—TOP2B—hematologic cancer	0.000313	0.317	CrCbGaD
Epirubicin—DHCR7—blood—hematologic cancer	0.000311	0.0247	CbGeAlD
Epirubicin—AURKA—testis—hematologic cancer	0.000307	0.0244	CbGeAlD
Epirubicin—DHCR7—bone marrow—hematologic cancer	0.000301	0.0239	CbGeAlD
Epirubicin—YWHAG—blood—hematologic cancer	0.000285	0.0226	CbGeAlD
Epirubicin—CHD1—lymph node—hematologic cancer	0.000276	0.0219	CbGeAlD
Epirubicin—YWHAG—bone marrow—hematologic cancer	0.000276	0.0219	CbGeAlD
Epirubicin—DHCR7—lung—hematologic cancer	0.000272	0.0216	CbGeAlD
Epirubicin—DHCR7—testis—hematologic cancer	0.000257	0.0204	CbGeAlD
Epirubicin—YWHAG—lung—hematologic cancer	0.00025	0.0198	CbGeAlD
Epirubicin—YWHAG—testis—hematologic cancer	0.000236	0.0187	CbGeAlD
Epirubicin—AURKA—lymph node—hematologic cancer	0.000223	0.0177	CbGeAlD
Epirubicin—UGT2B7—testis—hematologic cancer	0.000213	0.0169	CbGeAlD
Epirubicin—PLA2G4A—blood—hematologic cancer	0.000213	0.0169	CbGeAlD
Epirubicin—PLA2G4A—bone marrow—hematologic cancer	0.000206	0.0163	CbGeAlD
Epirubicin—TOP2A—blood—hematologic cancer	0.000202	0.016	CbGeAlD
Epirubicin—Valrubicin—TOP2A—hematologic cancer	0.0002	0.202	CrCbGaD
Epirubicin—TOP2A—bone marrow—hematologic cancer	0.000195	0.0155	CbGeAlD
Epirubicin—PLA2G4A—lung—hematologic cancer	0.000186	0.0148	CbGeAlD
Epirubicin—DHCR7—lymph node—hematologic cancer	0.000186	0.0148	CbGeAlD
Epirubicin—TOP2A—lung—hematologic cancer	0.000177	0.0141	CbGeAlD
Epirubicin—PLA2G4A—testis—hematologic cancer	0.000176	0.014	CbGeAlD
Epirubicin—YWHAG—lymph node—hematologic cancer	0.000171	0.0136	CbGeAlD
Epirubicin—TOP2A—testis—hematologic cancer	0.000167	0.0133	CbGeAlD
Epirubicin—PLA2G4A—lymph node—hematologic cancer	0.000127	0.0101	CbGeAlD
Epirubicin—ABCC1—blood—hematologic cancer	0.000122	0.00965	CbGeAlD
Epirubicin—TOP2A—lymph node—hematologic cancer	0.000121	0.00961	CbGeAlD
Epirubicin—Idarubicin—TOP2A—hematologic cancer	0.000115	0.116	CrCbGaD
Epirubicin—ABCC1—lung—hematologic cancer	0.000107	0.00846	CbGeAlD
Epirubicin—ABCC1—testis—hematologic cancer	0.000101	0.00799	CbGeAlD
Epirubicin—CHD1—Topotecan—Irinotecan—hematologic cancer	8.47e-05	0.0896	CbGdCrCtD
Epirubicin—ABCC1—lymph node—hematologic cancer	7.29e-05	0.00579	CbGeAlD
Epirubicin—Doxorubicin—NQO1—hematologic cancer	7.14e-05	0.0722	CrCbGaD
Epirubicin—Doxorubicin—ABCC3—hematologic cancer	7.02e-05	0.071	CrCbGaD
Epirubicin—Daunorubicin—TOP2A—hematologic cancer	6.15e-05	0.0622	CrCbGaD
Epirubicin—CHD1—Doxorubicin—Daunorubicin—hematologic cancer	5.72e-05	0.0605	CbGdCrCtD
Epirubicin—CHD1—Idarubicin—Daunorubicin—hematologic cancer	5.72e-05	0.0605	CbGdCrCtD
Epirubicin—Doxorubicin—TOP2A—hematologic cancer	4.99e-05	0.0505	CrCbGaD
Epirubicin—AURKA—Chlorambucil—Melphalan—hematologic cancer	4.82e-05	0.051	CbGdCrCtD
Epirubicin—CHD1—Doxorubicin—Idarubicin—hematologic cancer	4.33e-05	0.0459	CbGdCrCtD
Epirubicin—CHD1—Daunorubicin—Idarubicin—hematologic cancer	4.33e-05	0.0459	CbGdCrCtD
Epirubicin—Daunorubicin—ABCG2—hematologic cancer	4.2e-05	0.0425	CrCbGaD
Epirubicin—Doxorubicin—ABCG2—hematologic cancer	3.41e-05	0.0345	CrCbGaD
Epirubicin—AURKA—Topotecan—Irinotecan—hematologic cancer	2.78e-05	0.0295	CbGdCrCtD
Epirubicin—AURKA—Etoposide—Teniposide—hematologic cancer	2.77e-05	0.0293	CbGdCrCtD
Epirubicin—AURKA—Floxuridine—Pentostatin—hematologic cancer	1.92e-05	0.0203	CbGdCrCtD
Epirubicin—TOP2A—Nilotinib—Imatinib—hematologic cancer	1.92e-05	0.0203	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Daunorubicin—hematologic cancer	1.88e-05	0.0199	CbGdCrCtD
Epirubicin—AURKA—Doxorubicin—Daunorubicin—hematologic cancer	1.88e-05	0.0199	CbGdCrCtD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—hematologic cancer	1.84e-05	0.0195	CbGdCrCtD
Epirubicin—CHD1—Idarubicin—Doxorubicin—hematologic cancer	1.84e-05	0.0195	CbGdCrCtD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—hematologic cancer	1.77e-05	0.0187	CbGdCrCtD
Epirubicin—Daunorubicin—ABCB1—hematologic cancer	1.75e-05	0.0177	CrCbGaD
Epirubicin—AURKA—Menadione—Thalidomide—hematologic cancer	1.6e-05	0.0169	CbGdCrCtD
Epirubicin—AURKA—Cladribine—Pentostatin—hematologic cancer	1.45e-05	0.0154	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Idarubicin—hematologic cancer	1.43e-05	0.0151	CbGdCrCtD
Epirubicin—AURKA—Doxorubicin—Idarubicin—hematologic cancer	1.43e-05	0.0151	CbGdCrCtD
Epirubicin—Doxorubicin—ABCB1—hematologic cancer	1.42e-05	0.0144	CrCbGaD
Epirubicin—AURKA—Cladribine—Clofarabine—hematologic cancer	1.29e-05	0.0137	CbGdCrCtD
Epirubicin—AURKA—Teniposide—Etoposide—hematologic cancer	1.25e-05	0.0133	CbGdCrCtD
Epirubicin—AURKA—Cladribine—Nelarabine—hematologic cancer	1.22e-05	0.0129	CbGdCrCtD
Epirubicin—AURKA—Floxuridine—Cladribine—hematologic cancer	1.16e-05	0.0122	CbGdCrCtD
Epirubicin—AURKA—Clofarabine—Nelarabine—hematologic cancer	1.13e-05	0.0119	CbGdCrCtD
Epirubicin—TOP2A—Topotecan—Irinotecan—hematologic cancer	1.06e-05	0.0113	CbGdCrCtD
Epirubicin—TOP2A—Etoposide—Teniposide—hematologic cancer	1.06e-05	0.0112	CbGdCrCtD
Epirubicin—AURKA—Cytarabine—Clofarabine—hematologic cancer	1.02e-05	0.0108	CbGdCrCtD
Epirubicin—AURKA—Cytarabine—Nelarabine—hematologic cancer	9.58e-06	0.0101	CbGdCrCtD
Epirubicin—TOP2A—Vindesine—Vinorelbine—hematologic cancer	9.51e-06	0.0101	CbGdCrCtD
Epirubicin—AURKA—Cladribine—Fludarabine—hematologic cancer	9.5e-06	0.0101	CbGdCrCtD
Epirubicin—AURKA—Clofarabine—Fludarabine—hematologic cancer	8.78e-06	0.0093	CbGdCrCtD
Epirubicin—AURKA—Clofarabine—Cytarabine—hematologic cancer	8.3e-06	0.00878	CbGdCrCtD
Epirubicin—AURKA—Clofarabine—Cladribine—hematologic cancer	8.08e-06	0.00856	CbGdCrCtD
Epirubicin—TOP2A—Podofilox—Teniposide—hematologic cancer	8.06e-06	0.00853	CbGdCrCtD
Epirubicin—AURKA—Gemcitabine—Cytarabine—hematologic cancer	7.68e-06	0.00813	CbGdCrCtD
Epirubicin—TOP2A—Vindesine—Vinblastine—hematologic cancer	7.6e-06	0.00805	CbGdCrCtD
Epirubicin—TOP2A—Vindesine—Vincristine—hematologic cancer	7.6e-06	0.00805	CbGdCrCtD
Epirubicin—AURKA—Cytarabine—Fludarabine—hematologic cancer	7.48e-06	0.00791	CbGdCrCtD
Epirubicin—TOP2A—Floxuridine—Pentostatin—hematologic cancer	7.33e-06	0.00776	CbGdCrCtD
Epirubicin—TOP2A—Doxorubicin—Daunorubicin—hematologic cancer	7.19e-06	0.00761	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Daunorubicin—hematologic cancer	7.19e-06	0.00761	CbGdCrCtD
Epirubicin—AURKA—Cytarabine—Gemcitabine—hematologic cancer	7.06e-06	0.00747	CbGdCrCtD
Epirubicin—TOP2A—Menadione—Thalidomide—hematologic cancer	6.11e-06	0.00647	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Doxorubicin—hematologic cancer	6.06e-06	0.00641	CbGdCrCtD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—hematologic cancer	6.06e-06	0.00641	CbGdCrCtD
Epirubicin—TOP2A—Cladribine—Pentostatin—hematologic cancer	5.55e-06	0.00587	CbGdCrCtD
Epirubicin—TOP2A—Doxorubicin—Idarubicin—hematologic cancer	5.45e-06	0.00576	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Idarubicin—hematologic cancer	5.45e-06	0.00576	CbGdCrCtD
Epirubicin—TOP2A—Vincristine—Vinorelbine—hematologic cancer	5.13e-06	0.00543	CbGdCrCtD
Epirubicin—TOP2A—Cladribine—Clofarabine—hematologic cancer	4.95e-06	0.00524	CbGdCrCtD
Epirubicin—TOP2A—Vinorelbine—Vinblastine—hematologic cancer	4.8e-06	0.00508	CbGdCrCtD
Epirubicin—TOP2A—Vinorelbine—Vincristine—hematologic cancer	4.8e-06	0.00508	CbGdCrCtD
Epirubicin—TOP2A—Podofilox—Etoposide—hematologic cancer	4.79e-06	0.00507	CbGdCrCtD
Epirubicin—TOP2A—Teniposide—Etoposide—hematologic cancer	4.79e-06	0.00507	CbGdCrCtD
Epirubicin—TOP2A—Cladribine—Nelarabine—hematologic cancer	4.65e-06	0.00492	CbGdCrCtD
Epirubicin—TOP2A—Floxuridine—Cladribine—hematologic cancer	4.41e-06	0.00467	CbGdCrCtD
Epirubicin—TOP2A—Clofarabine—Nelarabine—hematologic cancer	4.3e-06	0.00455	CbGdCrCtD
Epirubicin—TOP2A—Vinblastine—Vinorelbine—hematologic cancer	4.13e-06	0.00437	CbGdCrCtD
Epirubicin—TOP2A—Vincristine—Vinblastine—hematologic cancer	4.1e-06	0.00434	CbGdCrCtD
Epirubicin—TOP2A—Cytarabine—Clofarabine—hematologic cancer	3.89e-06	0.00412	CbGdCrCtD
Epirubicin—TOP2A—Cytarabine—Nelarabine—hematologic cancer	3.66e-06	0.00387	CbGdCrCtD
Epirubicin—TOP2A—Cladribine—Fludarabine—hematologic cancer	3.63e-06	0.00384	CbGdCrCtD
Epirubicin—TOP2A—Clofarabine—Fludarabine—hematologic cancer	3.36e-06	0.00355	CbGdCrCtD
Epirubicin—TOP2A—Vinblastine—Vincristine—hematologic cancer	3.3e-06	0.00349	CbGdCrCtD
Epirubicin—TOP2A—Clofarabine—Cytarabine—hematologic cancer	3.17e-06	0.00335	CbGdCrCtD
Epirubicin—TOP2A—Azacitidine—Pentostatin—hematologic cancer	3.13e-06	0.00331	CbGdCrCtD
Epirubicin—TOP2A—Clofarabine—Cladribine—hematologic cancer	3.09e-06	0.00327	CbGdCrCtD
Epirubicin—TOP2A—Gemcitabine—Cytarabine—hematologic cancer	2.94e-06	0.00311	CbGdCrCtD
Epirubicin—TOP2A—Cytarabine—Fludarabine—hematologic cancer	2.86e-06	0.00302	CbGdCrCtD
Epirubicin—TOP2A—Azacitidine—Clofarabine—hematologic cancer	2.79e-06	0.00295	CbGdCrCtD
Epirubicin—TOP2A—Cytarabine—Gemcitabine—hematologic cancer	2.7e-06	0.00285	CbGdCrCtD
Epirubicin—TOP2A—Azacitidine—Nelarabine—hematologic cancer	2.62e-06	0.00278	CbGdCrCtD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—hematologic cancer	2.31e-06	0.00245	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—hematologic cancer	2.31e-06	0.00245	CbGdCrCtD
Epirubicin—TOP2A—Azacitidine—Fludarabine—hematologic cancer	2.05e-06	0.00217	CbGdCrCtD
Epirubicin—TOP2A—Azacitidine—Cytarabine—hematologic cancer	1.93e-06	0.00205	CbGdCrCtD
Epirubicin—TOP2A—Azacitidine—Gemcitabine—hematologic cancer	1.93e-06	0.00205	CbGdCrCtD
Epirubicin—TOP2A—Azacitidine—Cladribine—hematologic cancer	1.88e-06	0.00199	CbGdCrCtD
Epirubicin—PLA2G4A—Hemostasis—IL2—hematologic cancer	1.64e-06	7.06e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FBXW7—hematologic cancer	1.63e-06	7.04e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SDC1—hematologic cancer	1.63e-06	7.03e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTHLH—hematologic cancer	1.63e-06	7.03e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.63e-06	7e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MAPK3—hematologic cancer	1.61e-06	6.92e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2RA—hematologic cancer	1.61e-06	6.92e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—EP300—hematologic cancer	1.6e-06	6.91e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CYCS—hematologic cancer	1.6e-06	6.9e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HDAC2—hematologic cancer	1.6e-06	6.9e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CXCR4—hematologic cancer	1.6e-06	6.9e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTT1—hematologic cancer	1.6e-06	6.88e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—HSP90AA1—hematologic cancer	1.59e-06	6.86e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTGER4—hematologic cancer	1.59e-06	6.85e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD44—hematologic cancer	1.58e-06	6.82e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—LCK—hematologic cancer	1.58e-06	6.81e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.57e-06	6.77e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYCS—hematologic cancer	1.57e-06	6.77e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—MYC—hematologic cancer	1.56e-06	6.73e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CBL—hematologic cancer	1.56e-06	6.72e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—HSP90AA1—hematologic cancer	1.56e-06	6.72e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SDC1—hematologic cancer	1.56e-06	6.72e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—H3F3A—hematologic cancer	1.55e-06	6.68e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Dexamethasone—Betamethasone—hematologic cancer	1.52e-06	0.00161	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Dexamethasone—hematologic cancer	1.52e-06	0.00161	CbGdCrCtD
Epirubicin—PLA2G4A—Signaling Pathways—PRKCZ—hematologic cancer	1.51e-06	6.49e-05	CbGpPWpGaD
Epirubicin—Paraesthesia—Dexamethasone—hematologic cancer	1.5e-06	2.65e-05	CcSEcCtD
Epirubicin—Discomfort—Prednisone—hematologic cancer	1.5e-06	2.65e-05	CcSEcCtD
Epirubicin—Mental disorder—Methotrexate—hematologic cancer	1.5e-06	2.65e-05	CcSEcCtD
Epirubicin—Rash—Gemcitabine—hematologic cancer	1.5e-06	2.65e-05	CcSEcCtD
Epirubicin—Dermatitis—Gemcitabine—hematologic cancer	1.5e-06	2.65e-05	CcSEcCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.5e-06	6.44e-05	CbGpPWpGaD
Epirubicin—Hypersensitivity—Etoposide—hematologic cancer	1.49e-06	2.64e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.49e-06	6.42e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HSP90AA1—hematologic cancer	1.49e-06	6.41e-05	CbGpPWpGaD
Epirubicin—Erythema—Methotrexate—hematologic cancer	1.49e-06	2.63e-05	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—hematologic cancer	1.49e-06	2.63e-05	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—hematologic cancer	1.49e-06	2.63e-05	CcSEcCtD
Epirubicin—Headache—Gemcitabine—hematologic cancer	1.49e-06	2.63e-05	CcSEcCtD
Epirubicin—Nausea—Vincristine—hematologic cancer	1.49e-06	2.63e-05	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—hematologic cancer	1.48e-06	2.63e-05	CcSEcCtD
Epirubicin—PLA2G4A—Betamethasone—Triamcinolone—hematologic cancer	1.48e-06	0.00157	CbGdCrCtD
Epirubicin—PLA2G4A—Dexamethasone—Triamcinolone—hematologic cancer	1.48e-06	0.00157	CbGdCrCtD
Epirubicin—Hepatitis—Doxorubicin—hematologic cancer	1.48e-06	2.62e-05	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—hematologic cancer	1.48e-06	2.62e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Prednisolone—hematologic cancer	1.47e-06	2.61e-05	CcSEcCtD
Epirubicin—Hypoaesthesia—Doxorubicin—hematologic cancer	1.47e-06	2.61e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—EP300—hematologic cancer	1.47e-06	6.34e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.47e-06	6.34e-05	CbGpPWpGaD
Epirubicin—Pharyngitis—Doxorubicin—hematologic cancer	1.47e-06	2.6e-05	CcSEcCtD
Epirubicin—Dyspepsia—Dexamethasone—hematologic cancer	1.47e-06	2.6e-05	CcSEcCtD
Epirubicin—Dyspepsia—Betamethasone—hematologic cancer	1.47e-06	2.6e-05	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—hematologic cancer	1.46e-06	2.59e-05	CcSEcCtD
Epirubicin—Urticaria—Triamcinolone—hematologic cancer	1.46e-06	2.59e-05	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—hematologic cancer	1.46e-06	2.58e-05	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—hematologic cancer	1.46e-06	2.58e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PARP1—hematologic cancer	1.46e-06	6.27e-05	CbGpPWpGaD
Epirubicin—Asthenia—Etoposide—hematologic cancer	1.46e-06	2.58e-05	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—hematologic cancer	1.46e-06	2.58e-05	CcSEcCtD
Epirubicin—Body temperature increased—Triamcinolone—hematologic cancer	1.45e-06	2.57e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Prednisone—hematologic cancer	1.45e-06	2.57e-05	CcSEcCtD
Epirubicin—Oedema—Prednisone—hematologic cancer	1.45e-06	2.57e-05	CcSEcCtD
Epirubicin—Urethral disorder—Doxorubicin—hematologic cancer	1.45e-06	2.57e-05	CcSEcCtD
Epirubicin—Decreased appetite—Dexamethasone—hematologic cancer	1.45e-06	2.57e-05	CcSEcCtD
Epirubicin—Decreased appetite—Betamethasone—hematologic cancer	1.45e-06	2.57e-05	CcSEcCtD
Epirubicin—Nausea—Irinotecan—hematologic cancer	1.45e-06	2.56e-05	CcSEcCtD
Epirubicin—Nausea—Mitoxantrone—hematologic cancer	1.45e-06	2.56e-05	CcSEcCtD
Epirubicin—Infection—Prednisone—hematologic cancer	1.44e-06	2.56e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Betamethasone—hematologic cancer	1.44e-06	2.55e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	1.44e-06	2.55e-05	CcSEcCtD
Epirubicin—Back pain—Methotrexate—hematologic cancer	1.44e-06	2.55e-05	CcSEcCtD
Epirubicin—Fatigue—Betamethasone—hematologic cancer	1.44e-06	2.55e-05	CcSEcCtD
Epirubicin—Fatigue—Dexamethasone—hematologic cancer	1.44e-06	2.55e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—MAPK3—hematologic cancer	1.44e-06	6.19e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT1—hematologic cancer	1.44e-06	6.19e-05	CbGpPWpGaD
Epirubicin—Pruritus—Etoposide—hematologic cancer	1.43e-06	2.54e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FBXW7—hematologic cancer	1.43e-06	6.17e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SRC—hematologic cancer	1.43e-06	6.16e-05	CbGpPWpGaD
Epirubicin—Shock—Prednisone—hematologic cancer	1.43e-06	2.53e-05	CcSEcCtD
Epirubicin—Pain—Dexamethasone—hematologic cancer	1.43e-06	2.53e-05	CcSEcCtD
Epirubicin—Pain—Betamethasone—hematologic cancer	1.43e-06	2.53e-05	CcSEcCtD
Epirubicin—Visual impairment—Doxorubicin—hematologic cancer	1.43e-06	2.53e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Prednisone—hematologic cancer	1.43e-06	2.52e-05	CcSEcCtD
Epirubicin—Tachycardia—Prednisone—hematologic cancer	1.42e-06	2.51e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—GSTP1—hematologic cancer	1.41e-06	6.08e-05	CbGpPWpGaD
Epirubicin—Skin disorder—Prednisone—hematologic cancer	1.41e-06	2.5e-05	CcSEcCtD
Epirubicin—Nausea—Gemcitabine—hematologic cancer	1.41e-06	2.5e-05	CcSEcCtD
Epirubicin—PLA2G4A—Dexamethasone—Prednisone—hematologic cancer	1.41e-06	0.00149	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Prednisone—hematologic cancer	1.41e-06	0.00149	CbGdCrCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.41e-06	6.06e-05	CbGpPWpGaD
Epirubicin—Vomiting—Cisplatin—hematologic cancer	1.41e-06	2.49e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.41e-06	6.05e-05	CbGpPWpGaD
Epirubicin—Hyperhidrosis—Prednisone—hematologic cancer	1.41e-06	2.49e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CXCR4—hematologic cancer	1.4e-06	6.05e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HDAC2—hematologic cancer	1.4e-06	6.05e-05	CbGpPWpGaD
Epirubicin—Vision blurred—Methotrexate—hematologic cancer	1.4e-06	2.48e-05	CcSEcCtD
Epirubicin—Erythema multiforme—Doxorubicin—hematologic cancer	1.4e-06	2.48e-05	CcSEcCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—ALB—hematologic cancer	1.4e-06	6.03e-05	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—MYC—hematologic cancer	1.4e-06	6.02e-05	CbGpPWpGaD
Epirubicin—Rash—Cisplatin—hematologic cancer	1.4e-06	2.47e-05	CcSEcCtD
Epirubicin—Dermatitis—Cisplatin—hematologic cancer	1.39e-06	2.47e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—VEGFA—hematologic cancer	1.39e-06	6e-05	CbGpPWpGaD
Epirubicin—Diarrhoea—Etoposide—hematologic cancer	1.39e-06	2.46e-05	CcSEcCtD
Epirubicin—Anorexia—Prednisone—hematologic cancer	1.39e-06	2.45e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—GSTP1—hematologic cancer	1.39e-06	5.96e-05	CbGpPWpGaD
Epirubicin—Eye disorder—Doxorubicin—hematologic cancer	1.38e-06	2.45e-05	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—hematologic cancer	1.38e-06	2.44e-05	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—hematologic cancer	1.38e-06	2.44e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—NRAS—hematologic cancer	1.38e-06	5.93e-05	CbGpPWpGaD
Epirubicin—Anaemia—Methotrexate—hematologic cancer	1.38e-06	2.44e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Dexamethasone—hematologic cancer	1.38e-06	2.43e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Betamethasone—hematologic cancer	1.38e-06	2.43e-05	CcSEcCtD
Epirubicin—PLA2G4A—Dexamethasone—Prednisolone—hematologic cancer	1.37e-06	0.00146	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Prednisolone—hematologic cancer	1.37e-06	0.00146	CbGdCrCtD
Epirubicin—Flushing—Doxorubicin—hematologic cancer	1.37e-06	2.43e-05	CcSEcCtD
Epirubicin—Cardiac disorder—Doxorubicin—hematologic cancer	1.37e-06	2.43e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CBL—hematologic cancer	1.37e-06	5.89e-05	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Dexamethasone—hematologic cancer	1.36e-06	2.42e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Betamethasone—hematologic cancer	1.36e-06	2.42e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Triamcinolone—hematologic cancer	1.36e-06	2.4e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—IL3—hematologic cancer	1.35e-06	5.83e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—GRB2—hematologic cancer	1.34e-06	5.79e-05	CbGpPWpGaD
Epirubicin—Angiopathy—Doxorubicin—hematologic cancer	1.34e-06	2.38e-05	CcSEcCtD
Epirubicin—Malaise—Methotrexate—hematologic cancer	1.34e-06	2.38e-05	CcSEcCtD
Epirubicin—Dizziness—Etoposide—hematologic cancer	1.34e-06	2.37e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—PDGFA—hematologic cancer	1.34e-06	5.77e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.34e-06	5.77e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CG—hematologic cancer	1.34e-06	5.76e-05	CbGpPWpGaD
Epirubicin—Immune system disorder—Doxorubicin—hematologic cancer	1.34e-06	2.37e-05	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—hematologic cancer	1.34e-06	2.37e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—ABCB1—hematologic cancer	1.34e-06	5.76e-05	CbGpPWpGaD
Epirubicin—Mediastinal disorder—Doxorubicin—hematologic cancer	1.33e-06	2.36e-05	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—hematologic cancer	1.33e-06	2.36e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PTPN1—hematologic cancer	1.33e-06	5.73e-05	CbGpPWpGaD
Epirubicin—Chills—Doxorubicin—hematologic cancer	1.33e-06	2.35e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—NQO1—hematologic cancer	1.33e-06	5.71e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CD44—hematologic cancer	1.33e-06	5.71e-05	CbGpPWpGaD
Epirubicin—Urticaria—Betamethasone—hematologic cancer	1.33e-06	2.35e-05	CcSEcCtD
Epirubicin—Urticaria—Dexamethasone—hematologic cancer	1.33e-06	2.35e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Prednisone—hematologic cancer	1.32e-06	2.34e-05	CcSEcCtD
Epirubicin—Dizziness—Prednisolone—hematologic cancer	1.32e-06	2.34e-05	CcSEcCtD
Epirubicin—Arrhythmia—Doxorubicin—hematologic cancer	1.32e-06	2.34e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—KITLG—hematologic cancer	1.32e-06	5.69e-05	CbGpPWpGaD
Epirubicin—Asthenia—Triamcinolone—hematologic cancer	1.32e-06	2.34e-05	CcSEcCtD
Epirubicin—Abdominal pain—Betamethasone—hematologic cancer	1.32e-06	2.34e-05	CcSEcCtD
Epirubicin—Abdominal pain—Dexamethasone—hematologic cancer	1.32e-06	2.34e-05	CcSEcCtD
Epirubicin—Body temperature increased—Betamethasone—hematologic cancer	1.32e-06	2.34e-05	CcSEcCtD
Epirubicin—Body temperature increased—Dexamethasone—hematologic cancer	1.32e-06	2.34e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—MAPK3—hematologic cancer	1.32e-06	5.68e-05	CbGpPWpGaD
Epirubicin—Nausea—Cisplatin—hematologic cancer	1.32e-06	2.33e-05	CcSEcCtD
Epirubicin—Insomnia—Prednisone—hematologic cancer	1.31e-06	2.33e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PTPN11—hematologic cancer	1.31e-06	5.66e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ABCB1—hematologic cancer	1.31e-06	5.65e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RASGRP1—hematologic cancer	1.31e-06	5.64e-05	CbGpPWpGaD
Epirubicin—Alopecia—Doxorubicin—hematologic cancer	1.31e-06	2.32e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—HSP90AA1—hematologic cancer	1.31e-06	5.62e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SYK—hematologic cancer	1.31e-06	5.62e-05	CbGpPWpGaD
Epirubicin—Paraesthesia—Prednisone—hematologic cancer	1.31e-06	2.31e-05	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PIK3CA—hematologic cancer	1.3e-06	5.62e-05	CbGpPWpGaD
Epirubicin—Pruritus—Triamcinolone—hematologic cancer	1.3e-06	2.3e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	1.3e-06	5.6e-05	CbGpPWpGaD
Epirubicin—Cough—Methotrexate—hematologic cancer	1.3e-06	2.3e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—NCOR1—hematologic cancer	1.3e-06	5.59e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSTM1—hematologic cancer	1.3e-06	5.59e-05	CbGpPWpGaD
Epirubicin—Mental disorder—Doxorubicin—hematologic cancer	1.3e-06	2.3e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—STAT5A—hematologic cancer	1.29e-06	5.56e-05	CbGpPWpGaD
Epirubicin—Convulsion—Methotrexate—hematologic cancer	1.29e-06	2.28e-05	CcSEcCtD
Epirubicin—Vomiting—Etoposide—hematologic cancer	1.29e-06	2.28e-05	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—hematologic cancer	1.29e-06	2.28e-05	CcSEcCtD
Epirubicin—Erythema—Doxorubicin—hematologic cancer	1.29e-06	2.28e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—CDKN2B—hematologic cancer	1.28e-06	5.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TGFB1—hematologic cancer	1.28e-06	5.51e-05	CbGpPWpGaD
Epirubicin—Dyspepsia—Prednisone—hematologic cancer	1.28e-06	2.26e-05	CcSEcCtD
Epirubicin—Rash—Etoposide—hematologic cancer	1.28e-06	2.26e-05	CcSEcCtD
Epirubicin—Dermatitis—Etoposide—hematologic cancer	1.28e-06	2.26e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—CREB1—hematologic cancer	1.27e-06	5.48e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSTM1—hematologic cancer	1.27e-06	5.48e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NCOR1—hematologic cancer	1.27e-06	5.48e-05	CbGpPWpGaD
Epirubicin—Headache—Etoposide—hematologic cancer	1.27e-06	2.25e-05	CcSEcCtD
Epirubicin—Flatulence—Doxorubicin—hematologic cancer	1.27e-06	2.25e-05	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—hematologic cancer	1.27e-06	2.24e-05	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—hematologic cancer	1.27e-06	2.24e-05	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—hematologic cancer	1.27e-06	2.24e-05	CcSEcCtD
Epirubicin—Tension—Doxorubicin—hematologic cancer	1.26e-06	2.24e-05	CcSEcCtD
Epirubicin—Decreased appetite—Prednisone—hematologic cancer	1.26e-06	2.24e-05	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—hematologic cancer	1.26e-06	2.23e-05	CcSEcCtD
Epirubicin—Rash—Prednisolone—hematologic cancer	1.26e-06	2.23e-05	CcSEcCtD
Epirubicin—Dermatitis—Prednisolone—hematologic cancer	1.26e-06	2.23e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—STAT1—hematologic cancer	1.26e-06	5.42e-05	CbGpPWpGaD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	1.26e-06	2.23e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CYCS—hematologic cancer	1.26e-06	5.41e-05	CbGpPWpGaD
Epirubicin—Fatigue—Prednisone—hematologic cancer	1.25e-06	2.22e-05	CcSEcCtD
Epirubicin—Headache—Prednisolone—hematologic cancer	1.25e-06	2.22e-05	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—hematologic cancer	1.25e-06	2.22e-05	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—hematologic cancer	1.25e-06	2.22e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—HSP90AA1—hematologic cancer	1.25e-06	5.37e-05	CbGpPWpGaD
Epirubicin—Back pain—Doxorubicin—hematologic cancer	1.25e-06	2.21e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—CCL2—hematologic cancer	1.25e-06	5.37e-05	CbGpPWpGaD
Epirubicin—Constipation—Prednisone—hematologic cancer	1.24e-06	2.2e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6R—hematologic cancer	1.24e-06	5.35e-05	CbGpPWpGaD
Epirubicin—Muscle spasms—Doxorubicin—hematologic cancer	1.24e-06	2.19e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—CD86—hematologic cancer	1.24e-06	5.33e-05	CbGpPWpGaD
Epirubicin—Confusional state—Methotrexate—hematologic cancer	1.22e-06	2.17e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—HES1—hematologic cancer	1.22e-06	5.26e-05	CbGpPWpGaD
Epirubicin—Dizziness—Triamcinolone—hematologic cancer	1.22e-06	2.15e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Methotrexate—hematologic cancer	1.21e-06	2.15e-05	CcSEcCtD
Epirubicin—Vision blurred—Doxorubicin—hematologic cancer	1.21e-06	2.15e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—NCOR1—hematologic cancer	1.21e-06	5.23e-05	CbGpPWpGaD
Epirubicin—Infection—Methotrexate—hematologic cancer	1.21e-06	2.14e-05	CcSEcCtD
Epirubicin—Nausea—Etoposide—hematologic cancer	1.2e-06	2.13e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—FGF1—hematologic cancer	1.2e-06	5.17e-05	CbGpPWpGaD
Epirubicin—Feeling abnormal—Prednisone—hematologic cancer	1.2e-06	2.12e-05	CcSEcCtD
Epirubicin—Asthenia—Betamethasone—hematologic cancer	1.2e-06	2.12e-05	CcSEcCtD
Epirubicin—Asthenia—Dexamethasone—hematologic cancer	1.2e-06	2.12e-05	CcSEcCtD
Epirubicin—Ill-defined disorder—Doxorubicin—hematologic cancer	1.2e-06	2.12e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Methotrexate—hematologic cancer	1.19e-06	2.11e-05	CcSEcCtD
Epirubicin—Anaemia—Doxorubicin—hematologic cancer	1.19e-06	2.11e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Methotrexate—hematologic cancer	1.19e-06	2.11e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Prednisone—hematologic cancer	1.19e-06	2.1e-05	CcSEcCtD
Epirubicin—Nausea—Prednisolone—hematologic cancer	1.19e-06	2.1e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—KRAS—hematologic cancer	1.19e-06	5.1e-05	CbGpPWpGaD
Epirubicin—Agitation—Doxorubicin—hematologic cancer	1.18e-06	2.1e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—MAP2K1—hematologic cancer	1.18e-06	5.1e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—FOXO1—hematologic cancer	1.18e-06	5.1e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PDGFRB—hematologic cancer	1.18e-06	5.09e-05	CbGpPWpGaD
Epirubicin—Pruritus—Betamethasone—hematologic cancer	1.18e-06	2.09e-05	CcSEcCtD
Epirubicin—Pruritus—Dexamethasone—hematologic cancer	1.18e-06	2.09e-05	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—hematologic cancer	1.18e-06	2.09e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—GRB2—hematologic cancer	1.18e-06	5.07e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CD—hematologic cancer	1.18e-06	5.06e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PDGFA—hematologic cancer	1.18e-06	5.06e-05	CbGpPWpGaD
Epirubicin—Hyperhidrosis—Methotrexate—hematologic cancer	1.17e-06	2.08e-05	CcSEcCtD
Epirubicin—Vomiting—Triamcinolone—hematologic cancer	1.17e-06	2.07e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—PDGFRA—hematologic cancer	1.16e-06	5.01e-05	CbGpPWpGaD
Epirubicin—Malaise—Doxorubicin—hematologic cancer	1.16e-06	2.06e-05	CcSEcCtD
Epirubicin—Rash—Triamcinolone—hematologic cancer	1.16e-06	2.05e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—JAK1—hematologic cancer	1.16e-06	4.99e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PRKCG—hematologic cancer	1.16e-06	4.99e-05	CbGpPWpGaD
Epirubicin—Dermatitis—Triamcinolone—hematologic cancer	1.16e-06	2.05e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—KITLG—hematologic cancer	1.16e-06	4.99e-05	CbGpPWpGaD
Epirubicin—Vertigo—Doxorubicin—hematologic cancer	1.16e-06	2.05e-05	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—hematologic cancer	1.16e-06	2.05e-05	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—hematologic cancer	1.16e-06	2.05e-05	CcSEcCtD
Epirubicin—Urticaria—Prednisone—hematologic cancer	1.15e-06	2.04e-05	CcSEcCtD
Epirubicin—TOP2A—Methyltestosterone—Prednisone—hematologic cancer	1.15e-06	0.00122	CbGdCrCtD
Epirubicin—Leukopenia—Doxorubicin—hematologic cancer	1.15e-06	2.04e-05	CcSEcCtD
Epirubicin—Headache—Triamcinolone—hematologic cancer	1.15e-06	2.04e-05	CcSEcCtD
Epirubicin—Body temperature increased—Prednisone—hematologic cancer	1.15e-06	2.03e-05	CcSEcCtD
Epirubicin—Abdominal pain—Prednisone—hematologic cancer	1.15e-06	2.03e-05	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TP53—hematologic cancer	1.15e-06	4.94e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—MTHFR—hematologic cancer	1.15e-06	4.94e-05	CbGpPWpGaD
Epirubicin—Diarrhoea—Dexamethasone—hematologic cancer	1.14e-06	2.02e-05	CcSEcCtD
Epirubicin—Diarrhoea—Betamethasone—hematologic cancer	1.14e-06	2.02e-05	CcSEcCtD
Epirubicin—Palpitations—Doxorubicin—hematologic cancer	1.14e-06	2.02e-05	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—hematologic cancer	1.14e-06	2.01e-05	CcSEcCtD
Epirubicin—Loss of consciousness—Doxorubicin—hematologic cancer	1.13e-06	2.01e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—STAT5A—hematologic cancer	1.13e-06	4.87e-05	CbGpPWpGaD
Epirubicin—TOP2A—Methyltestosterone—Prednisolone—hematologic cancer	1.13e-06	0.00119	CbGdCrCtD
Epirubicin—PLA2G4A—Metabolism—MTHFR—hematologic cancer	1.13e-06	4.84e-05	CbGpPWpGaD
Epirubicin—Cough—Doxorubicin—hematologic cancer	1.12e-06	1.99e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.12e-06	4.83e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN2B—hematologic cancer	1.12e-06	4.83e-05	CbGpPWpGaD
Epirubicin—Convulsion—Doxorubicin—hematologic cancer	1.12e-06	1.98e-05	CcSEcCtD
Epirubicin—Hypertension—Doxorubicin—hematologic cancer	1.11e-06	1.97e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3R1—hematologic cancer	1.11e-06	4.78e-05	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	1.11e-06	1.96e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—GSTP1—hematologic cancer	1.11e-06	4.77e-05	CbGpPWpGaD
Epirubicin—Dizziness—Betamethasone—hematologic cancer	1.1e-06	1.95e-05	CcSEcCtD
Epirubicin—Dizziness—Dexamethasone—hematologic cancer	1.1e-06	1.95e-05	CcSEcCtD
Epirubicin—Insomnia—Methotrexate—hematologic cancer	1.1e-06	1.94e-05	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—hematologic cancer	1.1e-06	1.94e-05	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—hematologic cancer	1.1e-06	1.94e-05	CcSEcCtD
Epirubicin—Chest pain—Doxorubicin—hematologic cancer	1.1e-06	1.94e-05	CcSEcCtD
Epirubicin—Anxiety—Doxorubicin—hematologic cancer	1.09e-06	1.94e-05	CcSEcCtD
Epirubicin—Nausea—Triamcinolone—hematologic cancer	1.09e-06	1.93e-05	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—hematologic cancer	1.09e-06	1.93e-05	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	1.09e-06	1.93e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—PIK3CA—hematologic cancer	1.09e-06	4.69e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CD86—hematologic cancer	1.09e-06	4.67e-05	CbGpPWpGaD
Epirubicin—Discomfort—Doxorubicin—hematologic cancer	1.08e-06	1.92e-05	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—hematologic cancer	1.08e-06	1.92e-05	CcSEcCtD
Epirubicin—Somnolence—Methotrexate—hematologic cancer	1.08e-06	1.91e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—JAK2—hematologic cancer	1.08e-06	4.65e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MTHFR—hematologic cancer	1.07e-06	4.62e-05	CbGpPWpGaD
Epirubicin—Dry mouth—Doxorubicin—hematologic cancer	1.07e-06	1.9e-05	CcSEcCtD
Epirubicin—Hypersensitivity—Prednisone—hematologic cancer	1.07e-06	1.9e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.07e-06	4.61e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HES1—hematologic cancer	1.07e-06	4.61e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TERT—hematologic cancer	1.07e-06	4.61e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HLA-A—hematologic cancer	1.07e-06	4.61e-05	CbGpPWpGaD
Epirubicin—Dyspepsia—Methotrexate—hematologic cancer	1.07e-06	1.89e-05	CcSEcCtD
Epirubicin—DHCR7—Metabolism—AKT1—hematologic cancer	1.07e-06	4.59e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NCOR1—hematologic cancer	1.06e-06	4.58e-05	CbGpPWpGaD
Epirubicin—Vomiting—Dexamethasone—hematologic cancer	1.06e-06	1.88e-05	CcSEcCtD
Epirubicin—Vomiting—Betamethasone—hematologic cancer	1.06e-06	1.88e-05	CcSEcCtD
Epirubicin—Confusional state—Doxorubicin—hematologic cancer	1.06e-06	1.88e-05	CcSEcCtD
Epirubicin—Decreased appetite—Methotrexate—hematologic cancer	1.06e-06	1.87e-05	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—TP53—hematologic cancer	1.05e-06	4.54e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FGF1—hematologic cancer	1.05e-06	4.53e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CSF2—hematologic cancer	1.05e-06	4.53e-05	CbGpPWpGaD
Epirubicin—Rash—Betamethasone—hematologic cancer	1.05e-06	1.86e-05	CcSEcCtD
Epirubicin—Rash—Dexamethasone—hematologic cancer	1.05e-06	1.86e-05	CcSEcCtD
Epirubicin—Oedema—Doxorubicin—hematologic cancer	1.05e-06	1.86e-05	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—hematologic cancer	1.05e-06	1.86e-05	CcSEcCtD
Epirubicin—Dermatitis—Dexamethasone—hematologic cancer	1.05e-06	1.86e-05	CcSEcCtD
Epirubicin—Dermatitis—Betamethasone—hematologic cancer	1.05e-06	1.86e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—hematologic cancer	1.05e-06	1.86e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—ABCB1—hematologic cancer	1.05e-06	4.51e-05	CbGpPWpGaD
Epirubicin—Fatigue—Methotrexate—hematologic cancer	1.05e-06	1.85e-05	CcSEcCtD
Epirubicin—Headache—Dexamethasone—hematologic cancer	1.05e-06	1.85e-05	CcSEcCtD
Epirubicin—Headache—Betamethasone—hematologic cancer	1.05e-06	1.85e-05	CcSEcCtD
Epirubicin—Infection—Doxorubicin—hematologic cancer	1.05e-06	1.85e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—PDGFB—hematologic cancer	1.04e-06	4.5e-05	CbGpPWpGaD
Epirubicin—Asthenia—Prednisone—hematologic cancer	1.04e-06	1.85e-05	CcSEcCtD
Epirubicin—Pain—Methotrexate—hematologic cancer	1.04e-06	1.84e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FOXO1—hematologic cancer	1.04e-06	4.47e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PDGFRB—hematologic cancer	1.04e-06	4.46e-05	CbGpPWpGaD
Epirubicin—Shock—Doxorubicin—hematologic cancer	1.03e-06	1.83e-05	CcSEcCtD
Epirubicin—Nervous system disorder—Doxorubicin—hematologic cancer	1.03e-06	1.83e-05	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—hematologic cancer	1.03e-06	1.82e-05	CcSEcCtD
Epirubicin—Pruritus—Prednisone—hematologic cancer	1.03e-06	1.82e-05	CcSEcCtD
Epirubicin—Tachycardia—Doxorubicin—hematologic cancer	1.03e-06	1.82e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CB—hematologic cancer	1.03e-06	4.41e-05	CbGpPWpGaD
Epirubicin—Skin disorder—Doxorubicin—hematologic cancer	1.02e-06	1.81e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—TSC2—hematologic cancer	1.02e-06	4.4e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PDGFRA—hematologic cancer	1.02e-06	4.39e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTM1—hematologic cancer	1.02e-06	4.38e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NCOR1—hematologic cancer	1.02e-06	4.38e-05	CbGpPWpGaD
Epirubicin—Hyperhidrosis—Doxorubicin—hematologic cancer	1.02e-06	1.8e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—JAK1—hematologic cancer	1.02e-06	4.37e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PRKCG—hematologic cancer	1.02e-06	4.37e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—HRAS—hematologic cancer	1.01e-06	4.34e-05	CbGpPWpGaD
Epirubicin—Anorexia—Doxorubicin—hematologic cancer	1e-06	1.77e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Methotrexate—hematologic cancer	1e-06	1.77e-05	CcSEcCtD
Epirubicin—Diarrhoea—Prednisone—hematologic cancer	9.95e-07	1.76e-05	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—hematologic cancer	9.93e-07	1.76e-05	CcSEcCtD
Epirubicin—Nausea—Betamethasone—hematologic cancer	9.92e-07	1.75e-05	CcSEcCtD
Epirubicin—Nausea—Dexamethasone—hematologic cancer	9.92e-07	1.75e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	9.91e-07	4.27e-05	CbGpPWpGaD
Epirubicin—Hypotension—Doxorubicin—hematologic cancer	9.83e-07	1.74e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—FGFR3—hematologic cancer	9.82e-07	4.23e-05	CbGpPWpGaD
Epirubicin—Urticaria—Methotrexate—hematologic cancer	9.65e-07	1.71e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—PIK3CG—hematologic cancer	9.64e-07	4.15e-05	CbGpPWpGaD
Epirubicin—Dizziness—Prednisone—hematologic cancer	9.61e-07	1.7e-05	CcSEcCtD
Epirubicin—Abdominal pain—Methotrexate—hematologic cancer	9.6e-07	1.7e-05	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—hematologic cancer	9.6e-07	1.7e-05	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	9.58e-07	1.7e-05	CcSEcCtD
Epirubicin—Insomnia—Doxorubicin—hematologic cancer	9.51e-07	1.68e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—IL2RA—hematologic cancer	9.49e-07	4.08e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CG—hematologic cancer	9.45e-07	4.07e-05	CbGpPWpGaD
Epirubicin—Paraesthesia—Doxorubicin—hematologic cancer	9.45e-07	1.67e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—IL2—hematologic cancer	9.42e-07	4.05e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TERT—hematologic cancer	9.38e-07	4.04e-05	CbGpPWpGaD
Epirubicin—Dyspnoea—Doxorubicin—hematologic cancer	9.38e-07	1.66e-05	CcSEcCtD
Epirubicin—Somnolence—Doxorubicin—hematologic cancer	9.35e-07	1.66e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—BAD—hematologic cancer	9.31e-07	4.01e-05	CbGpPWpGaD
Epirubicin—Dyspepsia—Doxorubicin—hematologic cancer	9.26e-07	1.64e-05	CcSEcCtD
Epirubicin—Vomiting—Prednisone—hematologic cancer	9.24e-07	1.64e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—NOTCH1—hematologic cancer	9.22e-07	3.97e-05	CbGpPWpGaD
Epirubicin—Rash—Prednisone—hematologic cancer	9.17e-07	1.62e-05	CcSEcCtD
Epirubicin—Dermatitis—Prednisone—hematologic cancer	9.16e-07	1.62e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PDGFB—hematologic cancer	9.16e-07	3.94e-05	CbGpPWpGaD
Epirubicin—Decreased appetite—Doxorubicin—hematologic cancer	9.14e-07	1.62e-05	CcSEcCtD
Epirubicin—Headache—Prednisone—hematologic cancer	9.11e-07	1.61e-05	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	9.08e-07	1.61e-05	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—hematologic cancer	9.07e-07	1.61e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—CD80—hematologic cancer	9.03e-07	3.89e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KIT—hematologic cancer	9.02e-07	3.88e-05	CbGpPWpGaD
Epirubicin—Constipation—Doxorubicin—hematologic cancer	9e-07	1.59e-05	CcSEcCtD
Epirubicin—Pain—Doxorubicin—hematologic cancer	9e-07	1.59e-05	CcSEcCtD
Epirubicin—ABCC1—Metabolism—MTHFR—hematologic cancer	8.99e-07	3.87e-05	CbGpPWpGaD
Epirubicin—Hypersensitivity—Methotrexate—hematologic cancer	8.95e-07	1.58e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—TSC2—hematologic cancer	8.95e-07	3.85e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CREBBP—hematologic cancer	8.94e-07	3.85e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—AKT1—hematologic cancer	8.9e-07	3.83e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTPN11—hematologic cancer	8.86e-07	3.81e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CREBBP—hematologic cancer	8.76e-07	3.77e-05	CbGpPWpGaD
Epirubicin—Asthenia—Methotrexate—hematologic cancer	8.72e-07	1.54e-05	CcSEcCtD
Epirubicin—Feeling abnormal—Doxorubicin—hematologic cancer	8.67e-07	1.53e-05	CcSEcCtD
Epirubicin—Nausea—Prednisone—hematologic cancer	8.63e-07	1.53e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FGFR3—hematologic cancer	8.61e-07	3.71e-05	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Doxorubicin—hematologic cancer	8.6e-07	1.52e-05	CcSEcCtD
Epirubicin—Pruritus—Methotrexate—hematologic cancer	8.6e-07	1.52e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—CREB1—hematologic cancer	8.58e-07	3.7e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAPK14—hematologic cancer	8.52e-07	3.67e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—BRAF—hematologic cancer	8.48e-07	3.65e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CD—hematologic cancer	8.47e-07	3.65e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6R—hematologic cancer	8.37e-07	3.61e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—ALB—hematologic cancer	8.36e-07	3.6e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ESR1—hematologic cancer	8.36e-07	3.6e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CREBBP—hematologic cancer	8.36e-07	3.6e-05	CbGpPWpGaD
Epirubicin—Urticaria—Doxorubicin—hematologic cancer	8.36e-07	1.48e-05	CcSEcCtD
Epirubicin—Abdominal pain—Doxorubicin—hematologic cancer	8.32e-07	1.47e-05	CcSEcCtD
Epirubicin—Body temperature increased—Doxorubicin—hematologic cancer	8.32e-07	1.47e-05	CcSEcCtD
Epirubicin—Diarrhoea—Methotrexate—hematologic cancer	8.31e-07	1.47e-05	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—PIK3CD—hematologic cancer	8.31e-07	3.58e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—FN1—hematologic cancer	8.26e-07	3.56e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ALB—hematologic cancer	8.2e-07	3.53e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NFKBIA—hematologic cancer	8.16e-07	3.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—BAD—hematologic cancer	8.16e-07	3.51e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOTCH1—hematologic cancer	8.08e-07	3.48e-05	CbGpPWpGaD
Epirubicin—Dizziness—Methotrexate—hematologic cancer	8.03e-07	1.42e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—PIK3R1—hematologic cancer	8e-07	3.45e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MAP2K1—hematologic cancer	7.98e-07	3.44e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CD—hematologic cancer	7.93e-07	3.41e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	7.92e-07	3.41e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CD80—hematologic cancer	7.92e-07	3.41e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CG—hematologic cancer	7.9e-07	3.4e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KIT—hematologic cancer	7.9e-07	3.4e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—NRAS—hematologic cancer	7.9e-07	3.4e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3R1—hematologic cancer	7.85e-07	3.38e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTPN11—hematologic cancer	7.77e-07	3.34e-05	CbGpPWpGaD
Epirubicin—Hypersensitivity—Doxorubicin—hematologic cancer	7.75e-07	1.37e-05	CcSEcCtD
Epirubicin—Vomiting—Methotrexate—hematologic cancer	7.72e-07	1.37e-05	CcSEcCtD
Epirubicin—Rash—Methotrexate—hematologic cancer	7.66e-07	1.36e-05	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—hematologic cancer	7.65e-07	1.35e-05	CcSEcCtD
Epirubicin—Headache—Methotrexate—hematologic cancer	7.61e-07	1.35e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—FGF2—hematologic cancer	7.59e-07	3.27e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—MAPK3—hematologic cancer	7.57e-07	3.26e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CG—hematologic cancer	7.55e-07	3.25e-05	CbGpPWpGaD
Epirubicin—Asthenia—Doxorubicin—hematologic cancer	7.55e-07	1.34e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CREB1—hematologic cancer	7.52e-07	3.24e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3R1—hematologic cancer	7.49e-07	3.22e-05	CbGpPWpGaD
Epirubicin—Pruritus—Doxorubicin—hematologic cancer	7.44e-07	1.32e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—BRAF—hematologic cancer	7.43e-07	3.2e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CB—hematologic cancer	7.39e-07	3.18e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCL2—hematologic cancer	7.36e-07	3.17e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6R—hematologic cancer	7.34e-07	3.16e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CREBBP—hematologic cancer	7.33e-07	3.16e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—JAK2—hematologic cancer	7.28e-07	3.13e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CB—hematologic cancer	7.24e-07	3.12e-05	CbGpPWpGaD
Epirubicin—Nausea—Methotrexate—hematologic cancer	7.22e-07	1.28e-05	CcSEcCtD
Epirubicin—Diarrhoea—Doxorubicin—hematologic cancer	7.2e-07	1.27e-05	CcSEcCtD
Epirubicin—ABCC1—Disease—MDM2—hematologic cancer	7.1e-07	3.06e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CREBBP—hematologic cancer	7e-07	3.02e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAP2K1—hematologic cancer	6.99e-07	3.01e-05	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—hematologic cancer	6.96e-07	1.23e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CD—hematologic cancer	6.95e-07	2.99e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MTOR—hematologic cancer	6.91e-07	2.98e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CB—hematologic cancer	6.91e-07	2.98e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CD4—hematologic cancer	6.9e-07	2.97e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—KRAS—hematologic cancer	6.8e-07	2.93e-05	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—hematologic cancer	6.69e-07	1.18e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—FGF2—hematologic cancer	6.65e-07	2.86e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CD—hematologic cancer	6.64e-07	2.86e-05	CbGpPWpGaD
Epirubicin—Rash—Doxorubicin—hematologic cancer	6.63e-07	1.17e-05	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—hematologic cancer	6.63e-07	1.17e-05	CcSEcCtD
Epirubicin—Headache—Doxorubicin—hematologic cancer	6.59e-07	1.17e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3R1—hematologic cancer	6.56e-07	2.83e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ALB—hematologic cancer	6.55e-07	2.82e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1B—hematologic cancer	6.49e-07	2.79e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTEN—hematologic cancer	6.38e-07	2.75e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JAK2—hematologic cancer	6.38e-07	2.75e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3R1—hematologic cancer	6.27e-07	2.7e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTEN—hematologic cancer	6.26e-07	2.69e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—PIK3CA—hematologic cancer	6.25e-07	2.69e-05	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—hematologic cancer	6.25e-07	1.11e-05	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—MDM2—hematologic cancer	6.22e-07	2.68e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—EP300—hematologic cancer	6.09e-07	2.62e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CB—hematologic cancer	6.06e-07	2.61e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MTOR—hematologic cancer	6.06e-07	2.61e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—CDKN1A—hematologic cancer	5.98e-07	2.58e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTEN—hematologic cancer	5.97e-07	2.57e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—EP300—hematologic cancer	5.97e-07	2.57e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CB—hematologic cancer	5.79e-07	2.49e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—HRAS—hematologic cancer	5.78e-07	2.49e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EP300—hematologic cancer	5.69e-07	2.45e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1B—hematologic cancer	5.68e-07	2.45e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CASP3—hematologic cancer	5.57e-07	2.4e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL2—hematologic cancer	5.56e-07	2.39e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—SRC—hematologic cancer	5.54e-07	2.38e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—IL6—hematologic cancer	5.53e-07	2.38e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCND1—hematologic cancer	5.42e-07	2.33e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JUN—hematologic cancer	5.41e-07	2.33e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—STAT3—hematologic cancer	5.34e-07	2.3e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NRAS—hematologic cancer	5.33e-07	2.29e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CDKN1A—hematologic cancer	5.25e-07	2.26e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PTEN—hematologic cancer	5.23e-07	2.25e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAPK8—hematologic cancer	5.12e-07	2.2e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AKT1—hematologic cancer	5.11e-07	2.2e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MAPK3—hematologic cancer	5.1e-07	2.2e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTEN—hematologic cancer	5e-07	2.15e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EP300—hematologic cancer	4.99e-07	2.15e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MYC—hematologic cancer	4.96e-07	2.14e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TGFB1—hematologic cancer	4.95e-07	2.13e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SRC—hematologic cancer	4.85e-07	2.09e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—EP300—hematologic cancer	4.77e-07	2.05e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—VEGFA—hematologic cancer	4.73e-07	2.04e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—STAT3—hematologic cancer	4.68e-07	2.02e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NRAS—hematologic cancer	4.67e-07	2.01e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KRAS—hematologic cancer	4.59e-07	1.97e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PIK3CA—hematologic cancer	4.5e-07	1.94e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MAPK3—hematologic cancer	4.47e-07	1.93e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PIK3CA—hematologic cancer	4.42e-07	1.9e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MYC—hematologic cancer	4.35e-07	1.87e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TGFB1—hematologic cancer	4.34e-07	1.87e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PIK3CA—hematologic cancer	4.21e-07	1.81e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KRAS—hematologic cancer	4.02e-07	1.73e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—HRAS—hematologic cancer	3.9e-07	1.68e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—IL6—hematologic cancer	3.73e-07	1.61e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PIK3CA—hematologic cancer	3.69e-07	1.59e-05	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AKT1—hematologic cancer	3.68e-07	1.58e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AKT1—hematologic cancer	3.61e-07	1.55e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—hematologic cancer	3.57e-07	1.54e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PIK3CA—hematologic cancer	3.53e-07	1.52e-05	CbGpPWpGaD
Epirubicin—ABCC1—Disease—AKT1—hematologic cancer	3.44e-07	1.48e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—HRAS—hematologic cancer	3.42e-07	1.47e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IL6—hematologic cancer	3.27e-07	1.41e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AKT1—hematologic cancer	3.02e-07	1.3e-05	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AKT1—hematologic cancer	2.88e-07	1.24e-05	CbGpPWpGaD
